Differential effects of fingolimod on B-cell populations in multiple sclerosis

Multiple Sclerosis

Volumn 20, Issue 10, 2014, Pages 1371-1380

  Nakamura, Masakazu ^a,b   Matsuoka, Takako ^a   Chihara, Norio ^a   Miyake, Sachiko ^a,c   Sato, Wakiro ^c   Araki, Manabu ^c   Okamoto, Tomoko ^c   Lin, Youwei ^a,c   Ogawa, Masafumi ^c   Murata, Miho ^c   Aranami, Toshimasa ^a,c   Yamamura, Takashi ^a,c  

^a NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

Author keywords

B cells; CD138; CD38; Fingolimod; Memory B cell; Multiple sclerosis; Plasmablast; Proliferation; Resistance; Sphingosine 1 phosphate receptor 1

Indexed keywords

CD19 ANTIGEN; CD27 ANTIGEN; CD38 ANTIGEN; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CXCR3; FINGOLIMOD; HLA DR ANTIGEN; KI 67 ANTIGEN; MESSENGER RNA; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SYNDECAN 1; BIOLOGICAL MARKER; CD38 PROTEIN, HUMAN; IMMUNOSUPPRESSIVE AGENT; MEMBRANE PROTEIN; PROPANEDIOL DERIVATIVE; S1PR1 PROTEIN, HUMAN; SDC1 PROTEIN, HUMAN; SPHINGOSINE;

ADULT; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; GENE; GENE EXPRESSION; HUMAN; INTERNALIZATION; LYMPHOCYTE COUNT; LYMPHOCYTE MIGRATION; MALE; MEMORY CELL; MIDDLE AGED; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMABLAST; PROTEIN EXPRESSION; RECEPTOR BINDING; S1P1 GENE; ANALOGS AND DERIVATIVES; BLOOD; CASE CONTROL STUDY; COMPARATIVE STUDY; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PHENOTYPE; TIME; TREATMENT OUTCOME;

ADULT; ANTIGENS, CD38; B-LYMPHOCYTE SUBSETS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CELL PROLIFERATION; DRUG RESISTANCE; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOSUPPRESSIVE AGENTS; KI-67 ANTIGEN; LYMPHOCYTE ACTIVATION; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MULTIPLE SCLEROSIS; PHENOTYPE; PROPYLENE GLYCOLS; RECEPTORS, LYSOSPHINGOLIPID; RNA, MESSENGER; SPHINGOSINE; SYNDECAN-1; TIME FACTORS; TREATMENT OUTCOME;

EID: 84909992655     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458514523496     Document Type: Article

References (35)

1. Kivisakk P, Mahad DJ, Callahan MK, et al. Expression of CCR7 in multiple sclerosis: Implications for CNS immunity. Ann Neurol 2004; 55: 627-638.
2. Cyster JG and Schwab SR. Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs. Ann Rev Immunol 2012; 30: 69-94.
3. Cohen JA and Chun J. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. Ann Neurol 2011; 69: 759-777.
4. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362: 387-401.
5. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362: 402-415.
6. Mehling M, Lindberg R, Raulf F, et al. Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis. Neurology 2010; 75: 403-410.
7. Pilz G, Harrer A, Wipfler P, et al. Tumefactive MS lesions under fingolimod: A case report and literature review. Neurology 2013; 81: 1654-1658.
8. Jander S, Turowski B, Kieseier BC, et al. Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod. Mult Scler 2012; 18: 1650-1652.
9. Visser F, Wattjes MP, Pouwels PJ, et al. Tumefactive multiple sclerosis lesions under fingolimod treatment. Neurology 2012; 79: 2000-2003.
10. Leypoldt F, Munchau A, Moeller F, et al. Hemorrhaging focal encephalitis under fingolimod (FTY720) treatment: A case report. Neurology 2009; 72: 1022-1024.
11. Izaki S, Narukawa S, Kubota A, et al. [A case of neuromyelitis optica spectrum disorder developing a fulminant course with multiple white-matter lesions, following fingolimod treatment]. Rinsho Shinkeigaku 2013; 53: 513-517.
12. Min JH, Kim BJ and Lee KH. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler 2012; 18: 113-115.
13. Baranzini SE, Jeong MC, Butunoi C, et al. B-cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions. J Immunol 1999; 163: 5133-5144.
14. Qin Y, Duquette P, Zhang Y, et al. Clonal expansion and somatic hypermutation of V(H) genes of B cells from cerebrospinal fluid in multiple sclerosis. J Clin Invest 1998; 102: 1045-1050.
15. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358: 676-688.
16. Kowarik MC, Pellkofer HL, Cepok S, et al. Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS. Neurology 2011; 76: 1214-1221.
17. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292-302.
18. Takahashi T, Fujihara K, Nakashima I, et al. Establishment of a new sensitive assay for anti-human aquaporin-4 antibody in neuromyelitis optica. Tohoku J Exp Med 2006; 210: 307-313.
19. Chihara N, Aranami T, Sato W, et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci USA 2011; 108: 3701-3706.
20. Gohda M, Kunisawa J, Miura F, et al. Sphingosine 1-phosphate regulates the egress of IgA plasmablasts from Peyer's patches for intestinal IgA responses. J Immunol 2008; 180: 5335-5343.
21. Kabashima K, Haynes NM, Xu Y, et al. Plasma cell S1P1 expression determines secondary lymphoid organ retention versus bone marrow tropism. J Exp Med 2006; 203: 2683-2690.
22. Corcione A, Casazza S, Ferretti E, et al. Recapitulation of B-cell differentiation in the central nervous system of patients with multiple sclerosis. Proc Natl Acad Sci USA 2004; 101: 11064-11069.
23. Harp CT, Ireland S, Davis LS, et al. Memory B cells from a subset of treatment-naive relapsing-remitting multiple sclerosis patients elicit CD4(+) T-cell proliferation and IFNgamma production in response to myelin basic protein and myelin oligodendrocyte glycoprotein. Eur J Immunol 2010; 40: 2942-2956.
24. Ruffin N, Lantto R, Pensieroso S, et al. Immune activation and increased IL-21R expression are associated with the loss of memory B cells during HIV-1 infection. J Intern Med 2012; 272: 492-503.
25. Gerdes J, Lemke H, Baisch H, et al. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984; 133: 1710-1715.
26. Odendahl M, Mei H, Hoyer BF, et al. Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response. Blood 2005; 105: 1614-1621.
27. Chihara N, Aranami T, Oki S, et al. Plasmablasts as migratory IgG-producing cells in the pathogenesis of neuromyelitis optica. PLoS One 2013; 8: e83036.
28. Budde K, L Schmouder R Nashan B, et al. Pharmacodynamics of single doses of the novel immunosuppressant FTY720 in stable renal transplant patients. Am J Transpl 2003; 3: 846-854.
29. Vaessen LM, Van Besouw NM, Mol WM, et al. FTY720 treatment of kidney transplant patients: A differential effect on B cells, naive T cells, memory T cells and NK cells. Transpl Immunol 2006; 15: 281-288.
30. Mehling M, Brinkmann V, Antel J, et al. FTY720 therapy exerts differential effects on T-cell subsets in multiple sclerosis. Neurology 2008; 71: 1261-1267.
31. Johnson TA, Lapierre Y, Bar-Or A, et al. Distinct properties of circulating CD8+ T cells in FTY720-treated patients with multiple sclerosis. Arch Neurol 2010; 67: 1449-1455.
32. Johnson TA, Evans BL, Durafourt BA, et al. Reduction of the peripheral blood CD56(bright) NK lymphocyte subset in FTY720-treated multiple sclerosis patients. J Immunol 2011; 187: 570-579.
33. Nylander A and Hafler DA. Multiple sclerosis. J Clin Invest 2012; 122: 1180-1188.
34. Meinl E, Krumbholz M and Hohlfeld R. B-lineage cells in the inflammatory central nervous system environment: Migration, maintenance, local antibody production and therapeutic modulation. Ann Neurol 2006; 59: 880-892.
35. Von Budingen HC, Bar-Or A and Zamvil SS. B cells in multiple sclerosis: Connecting the dots. Curr Opin Immunol 2011; 23: 713-720.